FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519718874> ?p ?o ?g. }

• W2519718874 endingPage "S701" @default.
• W2519718874 startingPage "S700" @default.
• W2519718874 abstract "Chemotherapy for advanced NSCLC has gained widespread acceptance since it was demonstrated that cisplatin-based chemotherapy improved survival and quality of life.The aim of this study is to evaluate the feasibility in terms of overall survival, response rate and toxicity of the cisplatin-vinorelbine in Turkish patients with metastatic NSCLC. In this prospective study, ECOG performance 0-1, chemotherapy-naive stage IV NSCLC patients (pts) were treated with cisplatin (75 mg/m2, d1, IV) and vinorelbine (30 mg/m2, d1and d8, IV) every 21 days until progesion or unacceptable toxicity for a maximum of 6 cycles in single center. Tumor responses were evaluated by WHO criteia. Survival was calculated with the Kaplan-Meier method. Eight patients were still alive. For these patients, the survival was calculated until March 8, 2007. Between October 2001 and December 2006, a total of 46 NSCLC patients were treated. Two patients were not evaluable because we could not find his data file. Characteristics of patients were as follows: Median age 56 years (range 41-72), male 41, female 3 and PS 0 = 7 / 1 = 37. Histologic diagnosis was adenocarcinoma in 17 patients, squamous cell carcinoma in 5 and undifferentiated NSCLC in 22. Brain metastasis were present 7 patients (16%) prior starting the treatment. Median number of cycles were 3.0 (range 1-6). In 45 evaluable patients, complete responses were seen in 1 patient (2.3%), partial response in 15 (34.1%) and disease stabilization in 19 (43.2%). In total of 140 cycles, grade 3-4 neutropenia, grade 3-4 leukopenia and grade 3-4 anemia occured in 16.5%, 10% and 0.7% respectively. One fatal event was observed. The median survival was 285 days (95% CI [172-397]) and at 1 and 2 years survival were 39% and 9.5%, respectively. The combination of cisplatin plus vinorelbine is an active and tolerable regimen in Turkish patients with metastatic NSCLC." @default.
• W2519718874 created "2016-09-23" @default.
• W2519718874 creator A5006391790 @default.
• W2519718874 creator A5011969758 @default.
• W2519718874 creator A5012218477 @default.
• W2519718874 creator A5017524833 @default.
• W2519718874 creator A5058730472 @default.
• W2519718874 creator A5091818735 @default.
• W2519718874 date "2007-08-01" @default.
• W2519718874 modified "2023-09-26" @default.
• W2519718874 title "P2-321: Efficacy of cisplatin and vinorelbine in patients with metastatic NSCLC" @default.
• W2519718874 doi "https://doi.org/10.1097/01.jto.0000284029.05524.9c" @default.
• W2519718874 hasPublicationYear "2007" @default.
• W2519718874 type Work @default.
• W2519718874 sameAs 2519718874 @default.
• W2519718874 citedByCount "0" @default.
• W2519718874 crossrefType "journal-article" @default.
• W2519718874 hasAuthorship W2519718874A5006391790 @default.
• W2519718874 hasAuthorship W2519718874A5011969758 @default.
• W2519718874 hasAuthorship W2519718874A5012218477 @default.
• W2519718874 hasAuthorship W2519718874A5017524833 @default.
• W2519718874 hasAuthorship W2519718874A5058730472 @default.
• W2519718874 hasAuthorship W2519718874A5091818735 @default.
• W2519718874 hasBestOaLocation W25197188741 @default.
• W2519718874 hasConcept C121608353 @default.
• W2519718874 hasConcept C126322002 @default.
• W2519718874 hasConcept C143998085 @default.
• W2519718874 hasConcept C2776694085 @default.
• W2519718874 hasConcept C2777063308 @default.
• W2519718874 hasConcept C2778239845 @default.
• W2519718874 hasConcept C2780350996 @default.
• W2519718874 hasConcept C2781182431 @default.
• W2519718874 hasConcept C71924100 @default.
• W2519718874 hasConceptScore W2519718874C121608353 @default.
• W2519718874 hasConceptScore W2519718874C126322002 @default.
• W2519718874 hasConceptScore W2519718874C143998085 @default.
• W2519718874 hasConceptScore W2519718874C2776694085 @default.
• W2519718874 hasConceptScore W2519718874C2777063308 @default.
• W2519718874 hasConceptScore W2519718874C2778239845 @default.
• W2519718874 hasConceptScore W2519718874C2780350996 @default.
• W2519718874 hasConceptScore W2519718874C2781182431 @default.
• W2519718874 hasConceptScore W2519718874C71924100 @default.
• W2519718874 hasIssue "8" @default.
• W2519718874 hasLocation W25197188741 @default.
• W2519718874 hasOpenAccess W2519718874 @default.
• W2519718874 hasPrimaryLocation W25197188741 @default.
• W2519718874 hasRelatedWork W2027766979 @default.
• W2519718874 hasRelatedWork W2046463790 @default.
• W2519718874 hasRelatedWork W2336435704 @default.
• W2519718874 hasRelatedWork W2355256270 @default.
• W2519718874 hasRelatedWork W2355260394 @default.
• W2519718874 hasRelatedWork W2357026567 @default.
• W2519718874 hasRelatedWork W2363401756 @default.
• W2519718874 hasRelatedWork W2365070808 @default.
• W2519718874 hasRelatedWork W2389726776 @default.
• W2519718874 hasRelatedWork W2471989939 @default.
• W2519718874 hasVolume "2" @default.
• W2519718874 isParatext "false" @default.
• W2519718874 isRetracted "false" @default.
• W2519718874 magId "2519718874" @default.
• W2519718874 workType "article" @default.